Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Abstract The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Jeffrey S. Weber, Geoffrey T. Gibney, Ragini R. Kudchadkar, Bin Yu, Pingyan Cheng, Alberto J. Martinez, Jodie Kroeger, Allison Richards, Lori McCormick, Valerie E. Moberg, Heather Cronin, Xiuhua Zhao, Michael J. Schell, Y. Ann Chen
Format: Artigo
Jezik:engleski
Izdano: 2016
Online pristup:https://doi.org/10.1158/2326-6066.cir-15-0193
https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Internet

https://doi.org/10.1158/2326-6066.cir-15-0193
https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf

Slični predmeti